CN114222576A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN114222576A
CN114222576A CN202080057121.3A CN202080057121A CN114222576A CN 114222576 A CN114222576 A CN 114222576A CN 202080057121 A CN202080057121 A CN 202080057121A CN 114222576 A CN114222576 A CN 114222576A
Authority
CN
China
Prior art keywords
patient
administration
entrectinib
cancer
grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080057121.3A
Other languages
English (en)
Chinese (zh)
Inventor
乔治娜·梅内塞斯-洛伦特
埃德娜·周·曼内瓦尔
普拉蒂克·S·穆尔塔尼
苏珊·黛安·英格
塞尔吉奥·雷内·莱伊阿科斯塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Ignyta Inc
Original Assignee
F Hoffmann La Roche AG
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Ignyta Inc filed Critical F Hoffmann La Roche AG
Publication of CN114222576A publication Critical patent/CN114222576A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080057121.3A 2019-08-14 2020-08-13 治疗癌症的方法 Pending CN114222576A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886948P 2019-08-14 2019-08-14
US62/886,948 2019-08-14
PCT/US2020/046229 WO2021030619A1 (en) 2019-08-14 2020-08-13 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CN114222576A true CN114222576A (zh) 2022-03-22

Family

ID=72266851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080057121.3A Pending CN114222576A (zh) 2019-08-14 2020-08-13 治疗癌症的方法

Country Status (6)

Country Link
US (1) US20220257592A1 (enExample)
EP (1) EP4013404A1 (enExample)
JP (1) JP2022545387A (enExample)
CN (1) CN114222576A (enExample)
TW (1) TW202114676A (enExample)
WO (1) WO2021030619A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230454A1 (en) * 2022-05-24 2023-11-30 Icahn School Of Medicine At Mount Sinai Neurotrophic tyrosine receptor kinase inhibitors as therapeutics for liver disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
KR20230169457A (ko) * 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법

Also Published As

Publication number Publication date
TW202114676A (zh) 2021-04-16
EP4013404A1 (en) 2022-06-22
JP2022545387A (ja) 2022-10-27
WO2021030619A1 (en) 2021-02-18
US20220257592A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7061068B2 (ja) 癌治療のための併用薬
US20200129489A1 (en) Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
US10471120B2 (en) Peptidomimetic macrocycles and uses thereof
JP7203083B2 (ja) エントレクチニブを含む薬学的組成物
JP7311498B2 (ja) 薬学的組成物および剤形
US20170356918A1 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
JP2019527231A (ja) がんを治療するための組み合わせ
SG11202112061RA (en) Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer
TW202114676A (zh) 治療癌症之方法
HK40069081A (en) Methods of treating cancer
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
HK40016507A (en) Pharmaceutical compositions comprising entrectinib
BR122025029354A2 (pt) Método para preparar composição farmacêutica
HK1261529A1 (en) Combinations for the treatment of cancer
BR122024018560A2 (pt) Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin- 3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
EA045102B1 (ru) Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069081

Country of ref document: HK